Shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM – Get Rating) were up 2% on Tuesday . The company traded as high as $2.64 and last traded at $2.55. Approximately 125,887 shares traded hands during trading, an increase of 180% from the average daily volume of 44,959 shares. The stock had previously closed at $2.50.
Reneo Pharmaceuticals Price Performance
The firm has a market cap of $62.55 million, a P/E ratio of -1.28 and a beta of 0.50. The stock’s 50-day simple moving average is $2.30 and its two-hundred day simple moving average is $2.91.
Reneo Pharmaceuticals (NASDAQ:RPHM – Get Rating) last released its quarterly earnings results on Tuesday, November 8th. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.05. As a group, sell-side analysts expect that Reneo Pharmaceuticals, Inc. will post -2.16 earnings per share for the current year.
Institutional Trading of Reneo Pharmaceuticals
About Reneo Pharmaceuticals
Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.
- Get a free copy of the StockNews.com research report on Reneo Pharmaceuticals (RPHM)
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
- High-Yield, Deep-Value Verizon Puts In A Bottom
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
- Can Coty Stock Emerge in 2023 With Upside
Receive News & Ratings for Reneo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.